Alpha Teknova Inc. (TKNO)
Company Description
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally.
Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics.
The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions.
The company was founded in 1996 and is headquartered in Hollister, California.

Country | United States |
IPO Date | Jun 25, 2021 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 173 |
CEO | Jennifer Henry |
Contact Details
Address: 2290 Bert Drive Hollister, California United States | |
Website | https://www.teknova.com |
Stock Details
Ticker Symbol | TKNO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001850902 |
CUSIP Number | 02080L102 |
ISIN Number | US02080L1026 |
Employer ID | 94-3368109 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Jennifer Henry | Senior Vice President of Marketing |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 28, 2025 | ARS | Filing |
Apr 28, 2025 | DEFA14A | Filing |
Apr 28, 2025 | DEF 14A | Filing |
Mar 10, 2025 | S-8 | Filing |
Mar 07, 2025 | 10-K | Annual Report |
Mar 04, 2025 | 8-K | Current Report |
Feb 27, 2025 | 4 | Filing |
Nov 08, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Aug 30, 2024 | 424B3 | Filing |